Glucosinolates Market Size & Share 2026-2035
Download Free PDF
Report Content
Chapter 1. Research Methodology
1.1 Research approach
1.2 Quality Commitments
1.2.1 GMI AI policy & data integrity commitment
1.2.1.1 Source consistency protocol
1.3 Research Trail & Confidence Scoring
1.3.1 Research Trail Components
1.3.2 Scoring Components
1.4 Data Collection
1.4.1 Partial list of primary sources
1.5 Data mining sources
1.5.1 Paid sources
1.5.1.1 Sources, by region
1.6 Base estimates and calculations
1.6.1 Base year calculation
1.7 Forecast model
1.7.1 Quantified market impact analysis
1.7.1.1 Mathematical impact of growth parameters on forecast
1.8 Research transparency addendum
1.8.1 Source attribution framework
1.8.2 Quality assurance metrics
1.8.3 Our commitment to trust
Chapter 2. Executive Summary
2.1 Industry 360° synopsis
2.2 Key market trends
2.2.1 Type trends
2.2.2 Source trends
2.2.3 Application trends
2.2.4 Form trends
2.2.5 Regional trends
2.3 TAM Analysis, 2027–2035
2.4 CXO perspectives: strategic imperatives
Chapter 3. Industry Insights
3.1 Industry ecosystem analysis
3.1.1 Supplier Landscape
3.1.2 Profit Margin
3.1.3 Cost structure
3.1.4 Value addition at each stage
3.1.5 Factors affecting the value chain
3.1.6 Disruptions
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising global consumer demand for natural bioactive ingredients & plant-based nutraceuticals
3.2.1.2 Growing clinical evidence supporting glucosinolate-derived compounds in cancer prevention & metabolic health
3.2.1.3 Expanding biofumigation & biopesticide applications as sustainable alternatives to synthetic agrochemicals
3.2.1.4 Increasing integration of glucosinolates in personalized & precision nutrition formats
3.2.2 Industry pitfalls and challenges
3.2.2.1 Seasonal raw material supply volatility & geographic concentration of cruciferous crop production
3.2.2.2 High extraction, purification & stabilization costs limiting large-scale commercialization
3.2.2.3 Compound instability during thermal processing & supply chain degradation
3.2.2.4 Fragmented & inconsistent regulatory standards for health claims across regions
3.2.3 Market opportunities
3.2.3.1 Untapped pharmaceutical pipeline — sulforaphane-based investigational therapeutics in oncology, neurology & diabetes management
3.2.3.2 Rising functional food & nutraceutical adoption in emerging markets (India, Southeast Asia, Latin America)
3.2.3.3 Novel encapsulation & microencapsulation technologies enhancing bioavailability & shelf life
3.2.3.4 Strategic co-formulation opportunities in animal nutrition & precision livestock management
3.3 Growth potential analysis
3.4 Pricing Analysis (Driven by Primary Research)
3.4.1 Historical Price Trend Analysis by Glucosinolate Type (2022–2025) (Driven by Primary Research)
3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-plus) (Driven by Primary Research)
3.4.3 Price Benchmarking — Glucoraphanin vs. Sinigrin vs. Glucobrassicin (Driven by Primary Research)
3.4.4 Impact of Raw Material Seasonality on Finished Product Pricing (Driven by Primary Research)
3.5 Regulatory landscape
3.5.1 North America
3.5.2 Europe
3.5.3 Asia-Pacific
3.5.4 Latin America
3.5.5 Middle East and Africa
3.6 Porter's analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Threat of New Entrants
3.6.4 Threat of Substitute Products & Synthetic Alternatives
3.6.5 Intensity of Competitive Rivalry
3.7 PESTEL analysis
3.7.1 Political Factors
3.7.2 Economic Factors
3.7.3 Social Factors
3.7.4 Technological Factors
3.7.5 Environmental Factors
3.7.6 Legal Factors
3.8 Trade Data Analysis (Based on Paid Database)
3.8.1 Import/Export Volume & Value Trends by HS Code (2022–2025)
3.8.2 Key Trade Corridors & Tariff Impact
3.8.3 Bilateral Trade Agreements & Their Effect on Glucosinolate Ingredient Trade
3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
3.9.1 AI-Driven Disruption of Existing Business Models
3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
3.9.3 Risks, Limitations & Regulatory Considerations
3.10 Technology & Innovation Landscape
3.10.1 Extraction Technologies — Solvent, Supercritical Fluid (SFE), Ultrasonic & Enzyme-Assisted
3.10.2 Stabilization & Encapsulation Technologies
3.10.3 Fermentation-Based Glucosinolate Production
3.10.4 Myrosinase Activation & Controlled Hydrolysis Innovations
3.10.5 Emerging Bioengineering & Synthetic Biology Approaches
3.11 Supply Chain Analysis
3.11.1 Raw Material Sourcing Geography — Key Producing Countries & Seasonal Availability
3.11.2 Extraction Hub Concentration — China's Shaanxi & Shanxi Province Dominance
3.11.3 Cold Chain & Specialty Packaging Requirements
3.11.4 Supply Chain Risks — Climate Dependency, Crop Yield Variability & Logistics Gaps
3.11.5 Supply Chain Resilience Strategies — Vertical Integration & Multi-Sourcing
3.12 Capacity & Production Landscape (Driven by Primary Research)
3.12.1 Installed Extraction & Processing Capacity by Region & Key Producer (Driven by Primary Research)
3.12.2 Capacity Utilization Rates & Expansion Pipelines (2025–2030) (Driven by Primary Research)
Chapter 4. Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.2.1 By Region
4.2.1.1 North America
4.2.1.2 Europe
4.2.1.3 Asia-Pacific
4.2.1.4 Latin America
4.2.1.5 Middle East and Africa
4.2.2 Market Concentration Analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Key developments
4.5.1 Mergers & acquisitions
4.5.2 Partnerships & collaborations
4.5.3 New product launches
4.5.4 Expansion plans and funding
4.6 Company tier benchmarking
4.6.1 Tier classification criteria & qualifying thresholds
4.6.2 Tier positioning matrix by revenue, geography & innovation
Chapter 5. Glucosinolates Market Estimates & Forecast, By Type (USD Million, 2022–2035)
5.1 Aliphatic Glucosinolates
5.1.1 Sinigrin
5.1.2 Glucoraphanin
5.1.3 Glucoerucin
5.1.4 Others (Progoitrin, Gluconapin, Glucoiberverin)
5.2 Indolic Glucosinolates
5.2.1 Glucobrassicin
5.2.2 Neoglucobrassicin
5.2.3 Others (4-Methoxyglucobrassicin)
5.3 Aromatic Glucosinolates
5.3.1 Gluconasturtiin
5.3.2 Glucotropaeolin
5.3.3 Others
Chapter 6. Glucosinolates Market Estimates & Forecast, By Source (USD Million, 2022–2035)
6.1 Broccoli
6.1.1 Broccoli Florets
6.1.2 Broccoli Seeds
6.2 Mustard Seeds
6.2.1 Black Mustard (Brassica nigra)
6.2.2 Brown/Yellow Mustard (Brassica juncea / Sinapis alba)
6.3 Brussels Sprouts
6.4 Cabbage
6.5 Kale
6.6 Radish
6.7 Others (Watercress, Horseradish, Arugula, Papaya Seeds)
Chapter 7. Glucosinolates Market Estimates & Forecast, By Application (USD Million, 2022–2035)
7.1 Dietary Supplements & Nutraceuticals
7.1.1 Standalone Glucosinolate/Sulforaphane Supplements
7.1.2 Multi-Ingredient Blends & Antioxidant Formulations
7.2 Food & Beverages
7.2.1 Functional Foods & Fortified Products
7.2.2 Beverages (Juices, Health Drinks & Shots)
7.2.3 Food Additives & Flavor Enhancers
7.3 Pharmaceuticals
7.3.1 Oncology & Anti-Cancer Investigational Agents
7.3.2 Metabolic Disorders (Diabetes & Obesity)
7.3.3 Neuroprotection & CNS Therapeutics
7.4 Cosmetics & Personal Care
7.4.1 Anti-Aging & Skin Brightening Formulations
7.4.2 UV-Protection & Photoprotection Products
7.4.3 Hair Care Applications
7.5 Agriculture
7.5.1 Biofumigants & Soil Pest Management
7.5.2 Bioherbicides
7.5.3 Natural Nematicides & Fungicides
7.6 Animal Feed
7.6.1 Poultry Feed Additives
7.6.2 Aquaculture Nutrition
7.6.3 Swine & Ruminant Feed
Chapter 8. Glucosinolates Market Estimates & Forecast, By Form (USD Million, 2022–2035)
8.1 Powder
8.1.1 Spray-Dried Powder
8.1.2 Freeze-Dried Powder
8.2 Liquid/Extract
8.2.1 Standardized Liquid Extracts
8.2.2 Concentrated Aqueous Solutions
8.3 Capsules & Tablets
8.4 Oil
8.5 Granules
Chapter 9. Glucosinolates Market Estimates & Forecast, By Region (USD Million, 2022–2035)
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 UK
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 China
9.3.2 India
9.3.3 Japan
9.3.4 South Korea
9.3.5 Australia
9.3.6 Rest of Asia Pacific
9.4 Latin America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Rest of Latin America
9.5 Middle East & Africa
9.5.1 GCC Countries
9.5.2 South Africa
9.5.3 Rest of Middle East & Africa
Chapter 10. Company Profiles
Don't see your key competitors?
The companies listed in this report are a curated selection - not the full competitive universe.
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled. The profiles section spotlights strategically significant players; it does not define the scope of our market sizing.
Your competitive landscape may also include
Free customization - up to 20% of report value
Need specific data? Request customization and get the insights tailored to your exact requirements.
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at [email protected]
Share Content
Add Citations
Kiran Pulidindi. 2026, October. Glucosinolates Market 2026-2035 (Report ID: GMI4353). Global Market Insights Inc. Retrieved November 12, 2026, from https://www.gminsights.com/toc/details/glucosinolates-market
Glucosinolates Market
Get a free sample of this report
Glucosinolates Market Size
The glucosinolates market was valued at USD 215.0 million in 2025, projected to reach USD 228.0 million in 2026, growing at a 7.2% CAGR (2026–2035), and expected to reach USD 426.0 million by 2035.
The glucosinolates market comprises standardized glucosinolate ingredients and extracts supplied as enriched powders, liquid extracts, and encapsulated inputs to supplement, food, pharmaceutical, cosmetics, and agricultural formulators. At an average selling price of USD 126 per kilogram in 2025, the market remains a specialized botanical-ingredient category in which analytical consistency, compound stability, and documented supply-chain controls shape buyer qualification and purchasing decisions.
GMI Analyst View
Based on input from industry experts and supply-side analysis, we estimate that the global glucosinolates market processed approximately 1,706 metric tons of standardized ingredient volume in 2025. This volume base indicates commercial demand across dietary supplements, pharmaceutical-grade programs, and food and beverage formulations at a scale that supports dedicated GMP capacity, analytical standardization, and multijurisdictional compliance investment. We view extraction specificity and compound-stability management as increasingly important qualification barriers, favoring suppliers able to deliver consistent specifications rather than undifferentiated botanical extracts.
Glucosinolates Market Trends, Growth Drivers & GMI Forecast Outlook
Clinical validation, formulation innovation, and broader demand for traceable botanical actives are repositioning glucosinolates from a conventional supplement input toward a higher-specification ingredient category. Growth depends on pharmaceutical-grade procurement, stabilization technologies for food applications, and suppliers' ability to secure crop inputs while navigating health-claim restrictions.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Supplement manufacturers are the market's immediate commercial anchor because they can incorporate standardized glucoraphanin- and sinigrin-containing ingredients into established preventive-health, cellular-protection, and healthy-aging product lines. The commercial distinction rests on whether suppliers can substantiate active-compound consistency, manage raw-material variability, and support formulators with documentation suitable for branded claims and quality review.
Clinical programs may have a more consequential effect on product mix than on near-term volume. Human evidence increases the relevance of high-purity glucoraphanin grades to pharmaceutical and clinical-nutrition buyers, whose procurement specifications tend to emphasize traceability, impurity control, and lot-to-lot analytical reproducibility. Microbiome-responsive dosing concepts further favor suppliers that can provide tailored extract grades and technically supported delivery formats.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
European health-claim restrictions constrain the marketing latitude available to food and supplement brands, even where clinical interest in glucosinolate-derived compounds is increasing. Consequently, suppliers must compete through ingredient quality, traceability, formulation support, and business-to-business technical positioning rather than relying on consumer-facing disease or function claims. This creates a more deliberate commercialization pathway for premium formulations.
Raw-material exposure compounds the regulatory challenge. Broccoli-seed extraction and other brassica-based supply chains are sensitive to crop cycles, dedicated seed availability, storage conditions, and extraction controls. Thermal degradation adds a separate technical constraint in conventional food processing, making encapsulation, moisture protection, and controlled logistics central to expansion beyond capsules and stabilized powders.
GMI Analyst View
We see the forecast as a quality-and-execution story rather than a simple expansion in botanical demand. Suppliers that translate clinical relevance into validated specifications, stable delivery formats, and reliable crop sourcing should capture a greater share of incremental value, while suppliers dependent on generic extracts may face slower adoption in regulated and technically demanding applications.
Glucosinolates Market Segment Analysis
By Type
Aliphatic glucosinolates generated USD 118.3 million in 2025 and are projected to grow at a 6.8% CAGR (2026–2035). The glucosinolates market's aliphatic category benefits from the commercial maturity of glucoraphanin-rich broccoli inputs and broad acceptance in supplement manufacturing, but expanding extractor capacity and established buyer familiarity make specification control more important than basic availability.
Aromatic glucosinolates accounted for USD 32.3 million in 2025 and are anticipated to represent 14.6% of market revenue by 2035. Their role remains specialized, centered on watercress- and nasturtium-derived ingredients for functional foods, culinary formulations, and emerging antimicrobial applications, where sensory profile and compound identity guide formulation choices.
By Source Plant
Broccoli generated USD 96.8 million in 2025 and is projected to account for 44.1% of source-plant revenue by 2035. Its leading position reflects concentrated glucoraphanin availability and the depth of the associated clinical literature, although sustained leadership will require suppliers to maintain seed quality, extraction discipline, and documentation for pharmaceutical-adjacent buyers.
Mustard accounted for 20.0% of source-plant revenue in 2025 and is forecast to expand at a 7.1% CAGR (2026–2035). Sinigrin-rich mustard inputs are relevant to animal feed, biofumigation, and agriculture-oriented formulations, creating a distinct demand profile from the premium supplement emphasis that characterizes broccoli-derived extracts.
Cabbage is forecast to reach USD 41.9 million by 2035 and represented 10.0% of source-plant revenue in 2025. Its cost-competitive and comparatively mild sensory profile supports food-grade applications, allowing formulators to position cabbage-derived ingredients between broccoli's premium clinical association and more commodity-oriented agricultural inputs.
Brussels sprouts generated USD 17.2 million in 2025 and are projected to grow at a 7.4% CAGR (2026–2035). Their glucobrassicin content supports their relevance to indolic-glucosinolate extraction, particularly for suppliers targeting specialized nutraceutical, pharmaceutical, and cosmetics customers.
Kale represented 8.0% of source-plant revenue in 2025 and is expected to advance at a 7.7% CAGR (2026–2035). Strong consumer recognition and clean-label positioning make kale-derived ingredients particularly relevant to transparent-sourcing narratives in functional foods and beverages.
Radish generated USD 8.6 million in 2025 and is expected to represent 4.1% of source-plant revenue by 2035. Its niche is supported by glucoerucin- and glucoraphasatin-related applications, particularly where cosmetic formulators seek technically differentiated botanical actives.
Other source plants are projected to reach USD 23.1 million by 2035 and to grow at an 8.0% CAGR (2026–2035). Watercress, horseradish, nasturtium, wasabi, and arugula widen the addressable ingredient palette for premium beverages, culinary-nutraceutical concepts, and specialty antimicrobial applications.
By Application
Dietary supplements generated USD 90.3 million in 2025 and are forecast to account for 39.4% of application revenue by 2035. The segment remains the principal commercial base for the glucosinolates market, with standalone broccoli-extract products and multi-ingredient antioxidant blends supporting demand for consistent, readily formulatable ingredient grades.
Pharmaceutical applications are forecast to reach USD 77.5 million by 2035 and expand at a 9.1% CAGR (2026–2035). This channel's appeal lies in its preference for documented purity, defined active content, and dependable supply arrangements, which can raise the strategic value of GMP-grade production capabilities.
Cosmetics & personal care accounted for USD 25.8 million in 2025 and are expected to represent 12.8% of application revenue by 2035. Demand is linked to antioxidant and skin-protection positioning, with buyers favoring ingredient suppliers that can combine bioactive documentation with compatibility for topical formulation systems.
Agriculture generated USD 17.2 million in 2025 and is forecast to grow at a 6.5% CAGR (2026–2035). Biofumigation and natural crop-protection applications support demand, although registration requirements and competition from conventional agrochemicals can slow commercialization.
Animal feed is projected to reach USD 18.0 million by 2035 and represented 5.0% of application revenue in 2025. Granular, stable, and easily handled formats are especially relevant in this channel, where operational practicality and compliance with feed-input requirements influence adoption.
By Form
Powder generated USD 111.8 million in 2025 and is projected to represent 50.2% of form-segment revenue by 2035. Its leadership reflects compatibility with blending, encapsulation, and dry manufacturing operations, though buyers increasingly differentiate between commodity powder and grades supported by verified active-content specifications.
Liquid extract is expected to reach USD 78.2 million by 2035 and represented 18.0% of form-segment revenue in 2025. The format serves beverage and liquid-nutrition systems where powder reconstitution is less practical, but it requires strong stability management and formulation expertise.
Capsules/softgels represented 14.0% of form-segment revenue in 2025 and are forecast to grow at a 7.6% CAGR (2026–2035). Dose precision, consumer familiarity, and the continued expansion of direct-to-consumer supplement brands support this format's role in premium branded products.
Oil represented USD 17.2 million in 2025 and is projected to account for 8.0% of form-segment revenue by 2035. It remains a specialized option for cosmetic and personal-care systems requiring carrier compatibility, where technical formulation fit is more important than broad-volume use.
Granules generated USD 17.2 million in 2025 and are expected to expand at a 7.9% CAGR (2026–2035). Their handling characteristics suit animal feed and agricultural applications, where flowability, reduced dust, and dosing control can influence buyer preference.
GMI Analyst View
We interpret the segment structure as evidence of diversification in both value creation and technical requirements. Broccoli-based and powder-form supply remains commercially foundational, but higher-specification pharmaceutical, cosmetic, feed, and agriculture uses reward portfolio breadth. Suppliers able to manage multiple source plants, active profiles, and delivery forms should be better positioned than businesses concentrated in a single extract format.
Glucosinolates Market Regional Analysis
North America Glucosinolates Market Analysis
The glucosinolates market in North America represented 35.0% of global revenue in 2025 and is forecast to reach USD 145.1 million by 2035. The region's large supplement-manufacturing base, clinical-research infrastructure, and established distribution networks support demand for standardized botanical actives, while mature buyer requirements favor suppliers with documentation and dependable quality systems.
United States (U.S.)
The United States (U.S.) accounted for 32.0% of global revenue in 2025 and is expected to reach USD 133.1 million by 2035. Demand is reinforced by a deep nutraceutical manufacturing ecosystem and ongoing interest in broccoli-seed extracts across standalone supplements, antioxidant blends, and clinical-nutrition products.
Canada
Canada is projected to reach USD 12.0 million by 2035 and represented 3.0% of global revenue in 2025. Its natural-health-product framework and domestic brassica cultivation base support both demand for standardized extracts and a limited regional supply role.
Europe Glucosinolates Market Analysis
Europe generated USD 64.5 million in 2025 and is projected to represent 28.4% of global revenue by 2035. The glucosinolates market in Europe benefits from a quality-certification culture, advanced phytochemistry capabilities, and premium functional-food demand, although constraints on botanical health claims limit the commercial leverage of consumer-facing positioning.
Germany
Germany generated USD 19.4 million in 2025 and is expected to represent 8.6% of global revenue by 2035. Its role as a phytochemical-processing and distribution hub supports demand for suppliers able to meet rigorous traceability, quality, and certification expectations.
United Kingdom (UK)
The United Kingdom (UK) is projected to reach USD 23.9 million by 2035 and represented 6.0% of global revenue in 2025. Regulatory autonomy and an established health-food market create opportunities for differentiated botanical formulations, subject to product-specific authorization and claims requirements.
France
France represented 4.5% of global revenue in 2025 and is forecast to grow at a 6.3% CAGR (2026–2035). Its phytotherapy tradition and premium organic-food channels provide a receptive commercial base for clinically differentiated botanical ingredients.
Asia Pacific Glucosinolates Market Analysis
Asia Pacific is projected to reach USD 115.6 million by 2035 and grow at an 8.2% CAGR (2026–2035). The glucosinolates market in Asia Pacific combines a major extraction-supply base with rapidly expanding domestic demand, making regional production standards, local regulatory pathways, and online supplement distribution central to its commercial trajectory.
China
China accounted for 14.0% of global revenue in 2025 and is forecast to reach USD 65.4 million by 2035. Its importance extends beyond consumption: extraction capacity in Hunan, Shaanxi, and Zhejiang connects domestic supplement growth with global ingredient availability and pricing dynamics.
Japan
Japan generated USD 9.7 million in 2025 and is expected to represent 4.6% of global revenue by 2035. Structured functional-food pathways and sophisticated health-food retail channels support premium positioning for appropriately substantiated glucosinolate-containing formulations.
India
India generated USD 6.5 million in 2025 and is forecast to expand at an 8.6% CAGR (2026–2035). The country's mustard cultivation base and growing preventive-health demand give it dual strategic relevance as a potential supply source and an emerging consumption market.
Latin America Glucosinolates Market Analysis
Latin America represented 5.0% of global revenue in 2025 and is forecast to reach USD 22.2 million by 2035. The glucosinolates market in Latin America is primarily import-led, creating an opportunity for suppliers with distribution partners, regulatory knowledge, and products tailored to regional supplement and natural-health channels.
Brazil
Brazil represented 3.0% of global revenue in 2025 and is projected to reach USD 13.3 million by 2035. Its large consumer base, established botanical-product culture, and structured health-product environment support its role as the region's primary country market.
Mexico
Mexico generated USD 2.2 million in 2025 and is forecast to grow at a 7.2% CAGR (2026–2035). Expanding supplement manufacturing and cross-border production links can increase sourcing demand for standardized botanical ingredients.
Middle East & Africa (MEA) Glucosinolates Market Analysis
Middle East & Africa (MEA) generated USD 10.8 million in 2025 and is expected to represent 5.2% of global revenue by 2035. The glucosinolates market in MEA is import dependent, with demand concentrated in higher-income Gulf markets where premium nutraceutical consumption, health initiatives, and regional distribution infrastructure support uptake.
Saudi Arabia
Saudi Arabia represented 2.0% of global revenue in 2025 and is projected to reach USD 8.9 million by 2035. Wellness and food-diversification initiatives support institutional and consumer demand for premium functional ingredients.
United Arab Emirates (UAE)
The United Arab Emirates (UAE) generated USD 3.2 million in 2025 and is expected to represent 1.5% of global revenue by 2035. Its role as a specialty-ingredient trading and re-export hub enhances its importance beyond population-based domestic consumption.
GMI Analyst View
We expect regional competition to become more multipolar as Asia Pacific combines supply-scale advantages with rising domestic absorption, while North America retains its demand and formulation leadership. Europe remains strategically important for high-specification buyers but is constrained by claims governance. Latin America and MEA offer distribution-led growth opportunities for suppliers that can manage import logistics, local compliance, and premium positioning.
Glucosinolates Market Share & Competitive Landscape
The glucosinolates market share structure remains fragmented, with the top five companies collectively holding approximately 24% of 2025 market revenue. Competitive advantage is determined less by scale alone than by the ability to secure qualified brassica inputs, validate active content, provide regulatory documentation, and support customers across supplement, food, and pharmaceutical-adjacent applications.
Hunan Nutramax Inc. held approximately 8% of market revenue in 2025 and reported declared glucosinolate capacity of 120 metric tons per year. Its dedicated portfolio, extraction focus, and capacity to serve multiple end-use channels position the company around supply reliability and cost-efficient production of standardized glucoraphanin, sinigrin, and related ingredients.
Shaanxi Hongda Phytochemistry Co. Ltd. held approximately 5% of market revenue in 2025. Its vertical integration across mustard and broccoli raw materials supports positioning in agriculture, animal-feed, and nutraceutical applications, while export-oriented quality systems are important for European customer relationships.
Glanbia Nutritionals held approximately 4% of market revenue in 2025. Its TrueBroc ingredient contains 13% glucoraphanin and is produced under an exclusive license to Johns Hopkins University glucosinolate technology patents [5]Brassica Protection Products LLC. "TrueBroc - Glucoraphanin from Broccoli." brassica.com. Glanbia plc reported USD 3.9 billion in group revenue for FY2025, and its Health & Nutrition segment recorded 6.8% like-for-like revenue growth, giving the business commercial infrastructure for global supply agreements, formulation support, and continued evidence-led ingredient development [6]Glanbia plc. "Full Year 2025 Results." glanbia.com.
Xi'an Kintai Biological Technology Co. Ltd. and Zhejiang Skyherb Ingredients Inc. maintain focused positions through broader phytochemical portfolios, powder-form extract supply, and quality documentation for export-oriented supplement customers. Their competitive relevance illustrates the importance of regulatory-ready files, batch analytics, and channel access in a market where many producers operate at smaller scale.
Recent Industry Developments
Glanbia plc completed its acquisition of Scicore Nutra in early 2026 following the November 2025 agreement. The transaction expands Health & Nutrition capabilities in premix, flavor solutions, and nutritional-ingredient formulation, reinforcing the company's capacity to serve complex specialty-ingredient customers [6]Glanbia plc. "Full Year 2025 Results." glanbia.com.
Glanbia plc also reported 6.8% like-for-like revenue growth in its Health & Nutrition segment for FY2025. The performance supports continued investment in nutritional-ingredient capabilities relevant to customers seeking GMP-grade botanical and functional inputs [6]Glanbia plc. "Full Year 2025 Results." glanbia.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.